Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Part D Prior Auth Criteria | Op…
    Ask Trek AI about this page
    CurrentIndependent HealthPolicy N/A

    Medicare Part D Prior Authorization Criteria (selected drugs)

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization requirements for specified prescription drugs on Independent Health's 2025 Medicare Advantage Part D formularies; applies to prescribers and pharmacy staff submitting authorizations for Medicare Advantage members.

    Policy Summary
    PayerIndependent Health
    PolicyMedicare Part D Prior Authorization Criteria (selected drugs)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization before dispensing drugs listed with 'PA' on the Medicare Advantage Part D formularies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+listed products (partial)
    1 yeartypical coverage duration
    18+common age restriction
    specialtyrestricted prescribers

    Product-level Coverage Criteria

    OHTUVAYRE Initial Therapy

    Covered when ALL of the following are met:

    OHTUVAYRE initial criteria: Diagnosis of chronic obstructive pulmonary disease (COPD).
    Spirometry: Post-bronchodilator FEV1/FVC ratio < 0.72 and post-bronchodilator FEV1 percent predicted between >= 23% and <= 85%.FEV1/FVC <0.72; FEV1 23–85% predicted
    Symptoms: mMRC Dyspnea Scale score >= 2 (symptomatic).mMRC >=2
    Prior inhaled therapy: Currently receiving dual LABA–LAMA therapy with or without an inhaled corticosteroid (ICS), OR documentation that dual LABA–LAMA or triple LABA–LAMA–ICS therapy has been ineffective, not tolerated, or is contraindicated.

    Attestation or documentation of prior therapy required.

    Age: Patient is 18 years of age or older.>= 18 years
    Prescriber is a pulmonology specialist.
    Drug interactions/exclusions: Attestation OHTUVAYRE will not be used in combination with roflumilast.
    Coverage duration and reauthorization: Initial coverage 6 months; reauthorization to 1 year requires documentation of spirometry or clinical improvement from baseline and continued background LABA–LAMA therapy with or without ICS.

    ABILIFY MYCITE Initial Therapy

    Covered when ALL of the following are met:

    Diagnosis consistent with a covered indication for aripiprazole device (ABILIFY MYCITE).
    Age and prescriber: Patient is 18 years of age or older; prescriber is psychiatry.>=18 years
    Prior aripiprazole trial: Documentation of at least a one-month trial of generic aripiprazole (solution, tablets, or orally-disintegrating tablets) prior to approval for a new start.>= 1 month trial

    PA applies to new starts only.

    Coverage duration 1 year.

    ARIKAYCE Initial Therapy

    Covered when ALL of the following are met:

    Diagnosis of refractory Mycobacterium avium complex (MAC) lung disease.
    Prior multi-drug regimen failure: Documentation that a multi-drug regimen (eg, ethambutol, a macrolide, and a rifamycin) was tried and failed for at least a 6‑month trial period.>= 6 months
    Microbiology: Submission of a positive sputum culture result obtained after treatment with the multi-drug regimen.

    Microbiology documentation required.

    Age and prescriber: Patient is 18 years of age or older; prescriber restricted to infectious diseases or pulmonology.>=18 years
    Site of care/Part B vs Part D: Covered as a Part B benefit except for enrollees residing in a long-term care facility (Part D applies when dispensed under Part D rules).
    Coverage duration 1 year.

    PA applies when covered as Part D.

    NEXLETOL / NEXLIZET Initial Therapy

    Covered when ALL of the following are met:

    Diagnosis of the covered lipid disorder for which NEXLETOL or NEXLIZET is indicated.
    Age: Patient is 18 years of age or older.>=18 years
    Statin/ezetimibe requirement: Patient is currently using a statin plus ezetimibe OR has tried and failed or had intolerance to at least two statins, or one statin plus ezetimibe. At least one previously tried statin must be a hydrophilic statin.

    Document prior statin history for approval and reauthorization.

    Prescriber and starts: PA applies to new starts only.
    Coverage duration 1 year.

    Document ongoing use or intolerance for reauthorization.

    Biologic preferred-agent requirement

    Covered when ALL of the following class-level step requirements are met:

    Preferred-agent step therapy: For biologic and targeted immunomodulator drugs managed under this policy (except Otezla and Velsipity), patient must have tried and failed to have an adequate response to or had an intolerance to at least two preferred agents (eg, specified adalimumab biosimilar, Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, ustekinumab biosimilar, Xeljanz/XR) prior to approval where possible.

    Baseline latent TB screening required prior to initiation for most agents; yearly TB screening or chest X‑ray for reauthorization when exposure risk exists.

    TB screening: Submission of baseline latent tuberculosis screening (PPD or IGRA); if positive, delay until latent TB treated; yearly TB screening or chest X‑ray for reauthorization when exposure risk exists.
    Coverage duration 1 year.

    PA applies to all drugs in this class except where noted.

    CABLIVI Initial Therapy

    Covered when ALL of the following are met:

    Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) requiring caplacizumab (CABLIVI) in conjunction with plasma exchange and immunosuppressive therapy.
    Age and prescriber: Patient is 18 years of age or older; prescriber restricted to cardiology, hematology, or immunology.>=18 years
    Recurrence documentation: If not first use, submit documentation of prior aTTP recurrences while on caplacizumab; coverage will not be authorized if patient had >2 recurrences while on therapy.

    Recurrence-based denial rule applies.

    Coverage duration 3 months for initial authorization.

    PA applies to all.

    BRUKINSA Initial Therapy

    Covered when ALL of the following are met:

    Diagnosis consistent with an FDA‑approved indication for BRUKINSA.
    Pregnancy status: Submission of pregnancy status for females of childbearing potential.
    Prior therapy (follicular lymphoma): For follicular lymphoma, documentation of at least two prior systemic regimens tried and failed.
    Prescriber and age: Prescriber restricted to hematology/oncology; patient age >= 18 years.

    PA applies to new starts only; coverage duration 1 year.

    Drug interactions/exclusions: Coadministration with strong CYP3A inducers is an exclusion.

    CAMZYOS Initial and Maintenance

    Covered when ALL of the following are met (initial and maintenance):

    Diagnosis and symptoms: Diagnosis consistent with symptomatic obstructive hypertrophic cardiomyopathy and attestation patient has exertional symptoms consistent with NYHA class II or III.
    Hemodynamic and structural criteria: LV outflow tract (LVOT) gradient >= 50 mmHg (rest/Valsalva/after exercise) AND LV wall thickness >= 15 mm (>=13 mm if familial); submit current LVEF (must be >=55%).LVOT gradient >=50 mmHg; LV wall thickness >=15 mm (>=13 mm if familial); LVEF >=55%
    Prior therapy: Patient tried and failed or is intolerant/contraindicated to both a beta‑blocker and a non‑DHP calcium channel blocker; documentation of prior/current therapies required.
    Prescriber and age: Prescriber restricted to cardiology; patient age >= 18 years.
    Exclusions include coadministration with specified strong CYP inhibitors/inducers and certain concomitant cardiovascular drugs (see policy).
    Initial and reauthorization durations: Initial authorization 6 months; reauthorization requires documentation of a positive response to therapy for the initial reauthorization and maintenance of benefit for subsequent annual reauthorizations.

    CFTR Modulators

    Covered when ALL of the following are met:

    Diagnosis of cystic fibrosis for an FDA‑approved CFTR modulator indication.
    Genetic testing: Submission of CFTR mutation testing confirming presence of a CFTR gene mutation(s) responsive to the requested drug per product‑specific prescribing information (eg, ivacaftor‑responsive mutation, F508del requirements for combinations).

    Mutation confirmation required; lack of appropriate testing triggers denial.

    Age and prescriber: Prescriber restricted to pulmonology; age per product prescribing information.
    Exclusions: Coadministration with strong CYP3A inducers is an exclusion; Trikafta also excludes severe hepatic impairment per product labeling.

    PA applies to new starts only; coverage duration 1 year.

    CGRP Inhibitors Initial Therapy

    Covered when ALL of the following are met:

    Diagnosis and baseline: Diagnosis of covered migraine indication and submission of baseline headache days per month for prevention indications.
    Prior therapy: Patient tried and failed at least two non‑CGRP FDA‑approved or compendial alternatives for prevention (eg, propranolol, timolol, topiramate, valproic acid), or one if contraindicated. For certain products (eg, Emgality prevention) prior failure of other CGRP monoclonal antibodies may be required as specified.
    Age: Patient is 18 years of age or older (unless product labeling specifies otherwise).>=18 years
    Initial duration and reauthorization: Initial approval typically 3 months for prevention then 1 year; reauthorization requires documentation of improvement in on‑treatment headache days/month compared with baseline.

    PA applies to all.

    DOPTELET Indication-based Criteria

    Covered when the applicable INDICATION branch is met:

    Procedure‑related thrombocytopenia (DOPTELET): Platelet count < 50 x 10^9/L and patient scheduled for a procedure; prescriber restricted to gastroenterology, hematology, hepatology, or surgery; coverage duration 5 days.platelets <50 x10^9/L

    PA applies to all.

    Immune thrombocytopenia (ITP): Platelet count < 30 x 10^9/L OR platelet count < 50 x 10^9/L with symptomatic bleeding; documentation of splenectomy and/or tried and failed two different ITP therapies (systemic corticosteroids, IVIG, danazol, fostamatinib, or cytotoxics/immunosuppressants such as rituximab); prescriber restricted to gastroenterology/hematology/hepatology; initial 6 months then 1 year; reauthorization requires documented platelet improvement >= 50 x 10^9/L after at least 4 weeks on max tolerated dose.platelets <30 x10^9/L or <50 x10^9/L with bleeding
    Exclusion: Not approved to normalize platelet counts in chronic liver disease patients who are not scheduled for a procedure.

    Thrombocytopenia (procedure) and ITP criteria

    Covered when ALL of the following are met (procedure branch example):

    Thrombocytopenia for procedure: Diagnosis of thrombocytopenia with platelet count <50 x 10^9/L for patients with chronic liver disease scheduled to undergo a procedure; prescriber restricted to gastroenterology, hematology, hepatology, or surgery; coverage duration 5 days.platelets <50 x10^9/L

    PA applies to all.

    Dupilumab (indication-specific criteria)

    Covered when ALL applicable, indication‑specific requirements are met:

    Atopic dermatitis indication: Document prior and current therapies; at least 10% body surface area involvement; trial of a moderate‑strength topical corticosteroid for the specified duration unless contraindicated.BSA >=10%

    Initial coverage 6 months then 1 year; objective response required for continuation.

    Asthma indication: Pre‑bronchodilator FEV1 <80% predicted (or <90% if <18); blood eosinophils >=150 cells/mcL within 6 weeks OR chronic oral corticosteroid dependence; attestation dupilumab will be used in addition to other chronic therapies.FEV1 <80% or eos >=150

    Prescriber restricted to pulmonology or relevant specialty; objective response needed for reauthorization.

    EVRYSDI (spinal muscular atrophy)

    Covered when ALL of the following are met:

    Genetic confirmation: Diagnosis of spinal muscular atrophy (SMA) confirmed by genetic testing showing homozygous deletion of SMN1 exon 7 or compound heterozygosity for SMN1 exon 7 deletion and documentation of SMN2 copy number.genetic confirmation

    Prescriber restricted to neurology; initial 6 months then 1 year; maintenance or improvement in motor score required for reauthorization.

    Example enzyme replacement / genetic-condition product criteria

    Covered when ALL of the following are met (example enzyme‑replacement product):

    Genetic/variant confirmation: Diagnosis confirmed with submission of genetic or in‑vitro assay demonstrating an amenable gene variant as interpreted by a clinical genetics professional.

    Age and prescriber restrictions apply; severe renal impairment (eGFR <30) or ESRD on dialysis excluded.

    Age and prescriber: Patient age >=16 years; prescriber restricted to nephrology or genetic disease specialists.

    Coverage duration 1 year; PA applies to new starts only.

    Targeted oncology agents — required genetic/tumor testing and prior therapy

    Covered when ALL of the following are met (oncology/targeted therapy pattern):

    Molecular/tumor testing: Submission of test confirming presence of the required tumor mutation/fusion for the requested targeted agent (eg, RET, EGFR, IDH1, PIK3CA, FGFR, ALK, ROS1, NTRK as applicable).

    Lack of appropriate molecular testing will trigger denial.

    Prior therapy and intent: Submission of prior systemic therapies tried and failed when required by indication (eg, prior radioactive iodine for thyroid cancer, prior chemotherapy lines); documentation of life‑threatening or severe disease where required.

    Prescriber restricted to oncology; PA typically applies to new starts; coverage duration 1 year.

    Baseline safety: Submission of baseline vital signs and labs as specified per product (eg, baseline blood pressure for agents with hypertension risk; QTcF where required).

    Exclusions for strong CYP3A interactions and uncontrolled hypertension where specified.

    GLP-1/diabetes products

    Covered when ALL of the following are met:

    Diagnosis of type 2 diabetes: Documented diagnosis of type 2 diabetes by chart notes/ICD‑10 or laboratory criteria (eg, HbA1c >= 6.5%, fasting plasma glucose >=126 mg/dL, 2‑hour OGTT >=200 mg/dL, or random glucose >=200 mg/dL with symptoms).

    Attestation patient is not receiving another GLP‑1 agonist; PA applies to all; off‑label weight management excluded.

    Age and coverage: Age per product labeling; coverage duration 1 year.

    PA applies to all.

    Immune globulin clinical criteria

    Covered when ALL of the following are met (IG product general rules):

    Indication‑specific labs and documentation: Require diagnosis plus indication‑specific labs (eg, platelet count for ITP; IgG <600 mg/dL and history of serious bacterial infection for CLL; unequivocal CIDP diagnosis and intolerance/failure of systemic corticosteroids for >=3 months).

    For IV formulations, site‑of‑care details determine Part B vs Part D coverage; acute starts 3 months, chronic renewals 1 year; clinical response documentation required for continuation.

    Hereditary angioedema prophylaxis criteria

    Covered when ALL applicable, product‑specific prophylaxis vs acute‑use requirements are met:

    Prophylaxis vs acute distinction: Requests for prophylactic HAE therapy require objective documentation that prophylaxis is medically necessary (attack frequency, disease burden, QoL); acute‑use products required for attacks are excluded from prophylaxis and vice versa unless product labeling permits both and documentation supports use.

    Prescriber restricted to allergy/dermatology/hematology/immunology; PA applies to new starts only; coverage duration 1 year.

    Prior prophylactic therapy for Haegarda: For HAE prophylactic agents (eg, Haegarda) in patients >=12 years, documentation of prior prophylactic therapy failure or intolerance to Takhzyro is required when specified.

    Lab- and safety-dependent product criteria

    Covered when ALL of the following baseline lab and safety screening criteria are met:

    Baseline labs and safety screening: Submission of product‑specific baseline labs and safety tests as required (eg, liver function tests, ALP, Child‑Pugh score, 24‑hour UFC where required), and correction of electrolyte abnormalities prior to initiation where specified.

    Dose increases or continuations often require interim test results (eg, reduction in ALP after 6 months for elafibranor; 24‑hour UFC for Isturisa/Recorlev).

    Product-level PA criteria (summary)

    Covered when ALL of the following general product‑level PA documentation and restrictions are met:

    General product PA requirements: Meet diagnosis of covered use; provide required baseline or confirmatory tests per product; patient meets age and prescriber specialty restrictions; confirm pregnancy status for females of childbearing potential when required; disclose prior therapies and reason for failure/intolerance where required.

    PA applies to new starts unless otherwise noted; coverage durations vary by product (commonly 1 year).

    JOENJA

    Covered when ALL of the following are met:

    JOENJA initial approval: Submission of test confirming a pathogenic PIK3CD or PIK3R1 variant; liver function testing or Child‑Pugh score; negative pregnancy status or attestation re contraception; attestation patient is not using immunosuppressives; age >=12; prescriber specialist in genetic diseases or inborn errors of metabolism.

    Initial authorization 6 months then 1 year; objective benefit required for reauthorization.

    MG 5 MG

    Covered when ALL of the following are met:

    MG 5 mg initial approval: Documented genetic/biochemical diagnostic thresholds for severe familial hypercholesterolemia criteria (eg, functional LDL receptor mutations or equivalent biochemical criteria); submission of baseline liver tests and lipid panel; documentation of contraindication to or failure of evolocumab; age >=18; prescriber restricted to cardiology/lipidology/endocrinology experienced in lipid management.

    Initial authorization 6 months then 1 year; reauthorization requires LDL reduction documentation; not approved for heterozygous familial hypercholesterolemia.

    KERENDIA

    Covered when ALL of the following are met:

    KERENDIA initial approval: Submission of eGFR and baseline serum potassium; for heart failure specify LVEF >=40% and attestation patient is symptomatic despite therapy; age >=18; prescriber restriction for HF to cardiology where indicated; exclusions include eGFR <25, serum K >5.0 mEq/L, severe hepatic impairment and certain CYP3A4 interactions.

    For CKD with T2DM must document trial of Farxiga or Jardiance prior to approval.

    KISQALI

    Covered when ALL of the following are met:

    KISQALI initial approval: Submission of genetic tumor testing confirming HR‑positive/HER2‑negative disease; submission of QTcF, potassium, and magnesium within prior 6 months; pregnancy status for females of childbearing potential; confirm concomitant aromatase inhibitor or fulvestrant if Kisqali used as monotherapy; prescriber restricted to oncology; exclusions include congenital long QT syndrome, QTcF >= 450 msec, uncorrected electrolyte abnormalities, and coadministration with strong CYP3A4 inducers or QT‑prolonging drugs.

    Coverage duration 1 year.

    Lidocaine 5% patch / LIVTENCITY

    Covered when ALL of the following are met:

    Lidocaine 5% patch approval: Diagnosis consistent with an FDA‑approved indication (postherpetic neuralgia); patient age >=18; PA applies to all; requests for other indications will not be approved.

    Coverage duration 1 year.

    LIVTENCITY initial approval: Documented history of anti‑CMV medications tried and failed (at least one of cidofovir, foscarnet, ganciclovir, valganciclovir); age >=12; prescriber restricted to hematology/infectious diseases/oncology/transplant; coverage duration 8 weeks.

    PA applies to all.

    Ledipasvir-sofosbuvir

    Covered when ALL of the following are met (ledipasvir‑sofosbuvir example):

    Lab confirmation and genotype: Laboratory confirmation of HCV genotype (1a/1b/4/5/6 as appropriate) and submission of baseline HCV RNA level.

    Documentation of cirrhosis status and HBV testing (HBsAg and anti‑HBc) required.

    Treatment duration: Coverage duration per genotype and cirrhosis status (eg, treatment‑experienced genotype 1 with compensated cirrhosis 24 weeks; others 12 weeks).

    PA applies to all.

    Hepatitis C product requirements

    Covered when ALL of the following are met (HCV product general rules):

    HCV product requirements: Diagnosis of HCV with laboratory confirmation and genotype; documentation of cirrhosis presence and compensation status; submission of prior treatment history and HBV testing (HBsAg and anti‑HBc).

    Coverage durations follow AASLD‑IDSA guidance; PA applies to all.

    NUCALA coverage criteria

    Covered when ALL applicable indication criteria are met:

    NUCALA — asthma: Pre‑bronchodilator FEV1 below specified percent by age; blood eosinophil count >=150 cells/mcL within 6 weeks OR >=300 cells/mcL within 12 months; symptoms poorly controlled despite at least a 30‑day trial of inhaled corticosteroid plus another controller; attestation mepolizumab will be used in addition to other chronic therapies.eosinophil thresholds per policy

    PA applies to all; objective data required for reauthorization.

    NUCALA — CRSwNP: Documentation of nasal polyps and symptomatic nasal congestion; trial of intranasal corticosteroid for >=2 months or contraindication; attestation mepolizumab used in addition to intranasal corticosteroid if tolerated.

    Initial 6 months then 1 year; objective response required for continuation.

    Orilissa coverage and duration constraints

    Covered when ALL of the following are met (Orilissa constraints):

    Orilissa prerequisites: Attestation patient is premenopausal and pregnancy status confirmed; exclusions include pregnancy, severe hepatic impairment (Child‑Pugh C), known osteoporosis, and coadministration with OATP1B1 inhibitors.

    Duration limits apply (eg, up to 24 months depending on indication); requests >2 years will not be approved.

    Narcolepsy agent initial therapy requirements

    Covered when ALL of the following are met:

    Prior stimulant trial for narcolepsy agents: For adults with excessive daytime sleepiness associated with narcolepsy, patient previously tried and had inadequate response, intolerance, or contraindication to armodafinil or modafinil before alternative wakefulness agents will be authorized.

    PA applies to all; prescriber restrictions to neurology/sleep medicine for some agents.

    PCSK9 inhibitors prior therapy criteria

    Covered when ONE of the following is met:

    PCSK9 prior therapy: Patient is currently using a statin plus ezetimibe OR has tried and failed at least two statins OR one statin plus ezetimibe; at least one prior statin must be a hydrophilic statin.

    Documentation of prior statin history required for initial approval.

    PALYNZIQ initial and reauthorization criteria

    Covered when ALL of the following are met:

    Phenylalanine threshold: Blood phenylalanine concentration > 600 micromol/L while using sapropterin is required for initial approval of PALYNZIQ.>600 micromol/L

    Documentation of at least 30 days of prior sapropterin therapy and reduction in Phe required for reauthorization.

    Prior sapropterin therapy: Documentation patient has tried and failed to respond to at least 30 days of sapropterin therapy.>=30 days

    Pemazyre approval criteria

    Covered when ALL of the following are met:

    FGFR testing: Submission of testing confirming presence of FGFR1 rearrangement or FGFR2 fusion/rearrangement as applicable to the requested Pemazyre indication.
    Prior systemic therapy: Submission of prior systemic treatments tried for the indication as required by product labeling.

    Prescriber restricted to oncology; PA applies to new starts only; coverage duration 1 year.

    Recorlev initial criteria and monitoring

    Covered when ALL of the following are met:

    Biochemical and safety baseline: Submission of 24‑hour urine free cortisol (UFC) >1.5 x ULN, ECG including QTcF, and liver function tests within 3 months of request; documentation that pituitary surgery is not an option or was not curative.24‑hour UFC >1.5x ULN

    PA applies to all; initial 6 months then 1 year; continuation requires clinically relevant response (eg, UFC).

    Prior therapy failure: Documentation patient tried and failed at least one other therapy for Cushing's syndrome (eg, mifepristone, osilodrostat, pasireotide).

    Eltrombopag indication-specific criteria

    Covered when the applicable indication branch is met:

    Eltrombopag — ITP: Platelet count < 30 x 10^9/L OR < 50 x 10^9/L with increased bleeding risk AND documentation patient has undergone splenectomy and/or tried and failed two different ITP therapies (systemic corticosteroids, IVIG, danazol, fostamatinib, or cytotoxics/immunosuppressants such as rituximab).platelets <30 x10^9/L or <50 x10^9/L with bleeding

    Improvement in platelet count required for reauthorization after 12 weeks.

    Eltrombopag — chronic HCV thrombocytopenia: Platelet count < 75 x 10^9/L and attestation patient will receive interferon therapy to treat HCV.<75 x10^9/L
    Eltrombopag — aplastic anemia: Platelet count < 30 x 10^9/L and submission of concomitant immunosuppressive therapy plan or documentation of refractory disease with therapies tried/failed.<30 x10^9/L

    Relistor initial criteria

    Covered when ALL of the following are met:

    Mechanical obstruction exclusion: Known or suspected mechanical gastrointestinal obstruction and increased risk of recurrent obstruction are exclusions.
    Prior laxative therapy: Documentation patient has tried and failed, has a contraindication to, or could not tolerate both lubiprostone and naloxegol (Movantik); for non‑cancer pain, documentation of a steady opioid dose for the previous 8 weeks is required.steady opioid dose for previous 8 weeks

    Confirmation patient remains on opioid required for reauthorizations.

    RET-targeted therapy (RETEVMO)

    Covered when ALL of the following are met:

    RET inhibitor criteria: Submission of test confirming presence of RET gene fusion or mutation; baseline blood pressure; pregnancy status for females of childbearing potential; documentation of prior radioactive iodine for RET‑fusion thyroid cancer or prior systemic therapy for solid tumors as applicable.

    Age and indication‑specific restrictions apply; prescriber restricted to oncology; PA applies to new starts only; coverage duration 1 year.

    KMT2A-targeted therapy (REZLIDHIA/REZUROCK entries)

    Covered when ALL of the following are met:

    KMT2A‑targeted therapy criteria: Submission of test confirming KMT2A translocation (not 11q23 partial tandem duplication); baseline QTcF interval and baseline WBC count; pregnancy status for females of childbearing potential; prescriber restricted to hematology/oncology.exclude if QTcF >450 msec or WBC >25 x10^9/L

    PA applies to new starts only; coverage duration 1 year.

    Rare metabolic disorder therapies

    Covered when ALL of the following are met (representative rare metabolic disorder criteria):

    Primary hyperoxaluria therapy: Diagnosis confirmed with documentation of AGXT mutation by genetic testing or liver enzyme analysis; submission of 24‑hour urinary oxalate (Uox) >= 0.7 mmol (normalized for BSA if <18) and eGFR; attestation no prior kidney or liver transplant and not used in combination with lumasiran; prescriber restricted to nephrology/urology.Uox >=0.7 mmol/24h

    Initial 6 months then 1 year; reauthorization requires clinically relevant response (reduced Uox or plasma oxalate).

    Phenylketonuria therapy: Diagnosis of PKU with submission of blood phenylalanine concentration; initial approval requires Phe above threshold per policy and prior sapropterin failure; reduction in blood Phe required for reauthorization.>600 micromol/L where specified

    Prescriber and age restrictions as per product labeling.

    Atypical antipsychotics

    Covered when ALL of the following are met:

    Atypical antipsychotic step therapy: Diagnosis of covered psychiatric indication; prescriber restricted to psychiatry; PA applies to new starts only; exclusion: dementia‑related psychosis.

    For schizophrenia or acute mania/mixed bipolar I, patient must have tried and failed or been intolerant to aripiprazole and at least one other generic second‑generation atypical antipsychotic as specified.

    Sedative-hypnotic restriction for older adults

    Covered when ALL of the following are met:

    Geriatric sedative‑hypnotic restriction: Patient is 65 years of age or older; documentation that at least two alternative sedative‑hypnotics (eg, Belsomra, doxepin tablets, ramelteon, trazodone) were tried and were ineffective or not tolerated.

    PA applies to new starts only; coverage duration 1 year.

    HCV direct-acting antiviral criteria

    Covered when ALL of the following are met (HCV DAA example):

    DAA therapy criteria: Diagnosis of HCV with laboratory confirmation; submission of baseline HCV RNA and genotype; documentation of cirrhosis presence and compensation status; HBV testing (HBsAg and anti‑HBc) completed; prior treatment history submitted where relevant.

    Coverage duration per product and clinical scenario (commonly 12 weeks).

    The following supplemental exclusions and coverage notes summarize recurrent, medium‑importance conditions across product entries in this index and are intended to guide authorization decisions and documentation submissions. These are not exhaustive; reviewers must refer to each drug’s product‑specific section for definitive exclusion language and required supporting evidence.

    - Pregnancy and female reproductive risk: Several products list pregnancy as an absolute exclusion or require a negative pregnancy test and contraception attestation for females of childbearing potential; pregnancy status must be submitted where indicated. (Examples: multiple oncology, genetic, and endocrine agents.)

    - Severe hepatic impairment and specific liver disease states: Multiple products are excluded for Child‑Pugh class B or C or active/decompensated cirrhosis; liver function tests and Child‑Pugh scoring are required where noted. (See entries requiring LFTs or noting cirrhosis exclusions.)

    - Renal function limits: Several therapies exclude use with eGFR <30 mL/min/1.73 m2 or end‑stage renal disease; creatinine clearance or eGFR must be submitted when prompted to establish eligibility. Certain formulations (or indications) also have age or eGFR minimums.

    - Drug‑drug interactions and enzyme‑mediated exclusions: Coadministration with strong CYP3A4 inducers or inhibitors, P‑gp inhibitors, or other specified interacting drugs is a common exclusion; therapy will be denied if prohibited concomitant medications are present. Product pages specify which interactions are disqualifying.

    - QT interval and cardiac exclusions: History of congenital long QT syndrome, torsades de pointes, significant baseline QTcF above the stated threshold, uncorrected electrolyte abnormalities, or unstable cardiac disease are frequent exclusions for QT‑prolonging drugs; an ECG (QT/QTcF) and electrolytes may be required.

    - Indication‑specific noncoverage: Several products will not be authorized for certain off‑label uses under Medicare Part D (for example, GLP‑1 agonists for weight management and specified tadalafil strengths for erectile dysfunction per the index). Other exclusion examples include non‑refractory disease states (e.g., ARIKAYCE for non‑refractory MAC lung disease) or indications lacking evidence (e.g., metreleptin for generalized obesity not due to congenital leptin deficiency).

    - Mechanical or structural contraindications: Known or suspected mechanical gastrointestinal obstruction is an exclusion for agents affecting GI motility; prior cholecystectomy or biliary obstruction may exclude other products. These anatomic or structural risks must be documented when relevant.

    - Genotype/molecular exclusions: Lack of confirmatory testing for required molecular markers (CFTR, RET, FGFR, ALK/ROS1, PIK3CA, KMT2A, etc.) is an automatic basis for non‑approval; when genetic or tumor testing is required, the specific assay result must be submitted.

    - Prior‑therapy and step‑requirements: Many approvals require documented trials and failures (or intolerance/contraindication) of one or more listed prior therapies — e.g., statin/ezetimibe for certain lipid agents, specific non‑CGRP migraine preventives prior to CGRP inhibitors, and preferred biologic agents before more costly targeted immunomodulators. Failure to document these trials is a common denial risk.

    - Safety‑monitoring prerequisites and short course limits: Some agents require controlled initiation environments and monitoring (e.g., tolvaptan initiation with close sodium monitoring and a 30‑day limit; rifaximin 550 mg is restricted to specified course durations such as 14‑day courses for IBS‑D/SIBO with annual course limits).

    Indexed Product Coding & Key Numeric Thresholds

    Indexed product listings (sample)mixed
    XPOVIO (various oral tablet therapy pack doses)Multiple XPOVIO oral tablet therapy pack dose/frequency presentations listed in document
    Indexed drug formulations (LENVIMA)mixed
    LENVIMA (10 MG DAILY DOSE)listed in index (see source)
    LENVIMA (12 MG DAILY DOSE)listed in index (see source)
    LENVIMA (14 MG DAILY DOSE)listed in index (see source)
    Indexed drug formulations (NEUPOGEN)mixed
    NEUPOGEN INJECTION SOLUTION 300 MCG/MLlisted in index (see source)
    NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGElisted in index (see source)
    Sample product strengths (dasatinib)mixed
    dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mgListed product strengths as presented
    No explicit codes in partial extractmixed
    N/ANo explicit CPT/HCPCS/ICD codes listed in this extract
    Products listed (examples of formatting in document)mixed
    dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mgListed product strengths as presented
    No explicit billing/CPT/HCPCS/NDC codes in this excerptmixed
    No codes listed
    Covered product names (excerpt)NDC/mixedCovered
    VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MGProduct listed under PA criteria
    Covered product names (excerpt)mixedCovered
    VEOZAHProduct listed under PA criteria
    Covered product names (continued)mixedCovered
    VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MGProduct listed under PA criteria
    VIBERZIProduct listed under PA criteria
    VIJOICE ORAL PACKET / TABLETProduct listed under PA criteria
    VITRAKVI ORAL CAPSULE / SOLUTIONProduct listed under PA criteria
    VIVJOAProduct listed under PA criteria
    VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MGProduct listed under PA criteria
    AUSTEDO (various)Product listed under PA criteria
    VONJOProduct listed under PA criteria
    VOQUEZNA ORAL TABLET 10 MG, 20 MGProduct listed under PA criteria
    VORANIGO ORAL TABLET 10 MG, 40 MGProduct listed under PA criteria
    1–10 of 17
    1/2
    Indexed drug formulations (sample)mixed
    LENVIMA (10 MG DAILY DOSE)listed in index (see source)
    LENVIMA (12 MG DAILY DOSE)listed in index (see source)
    LENVIMA (14 MG DAILY DOSE)listed in index (see source)
    More indexed drug formulationsmixed
    NEUPOGEN INJECTION SOLUTION 300 MCG/MLlisted in index (see source)
    NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGElisted in index (see source)
    NEXLETOLlisted in index (see source)
    Key numeric and clinical thresholds
    FEV1 % predicted>= 23% and <= 85%
    FEV1/FVC ratio (post-bronchodilator)< 0.72
    QTcF interval (exclusion threshold)>450 msec (specified exclusion for some agents; CAPRELSA uses <=450 msec at baseline)
    Platelet-count thresholdsProcedural thrombocytopenia: <50 x10^9/L; ITP: <30 x10^9/L or <50 x10^9/L with symptomatic bleeding
    24-hour urine free cortisol (UFC)>1.5 x ULN (e.g., >50 micrograms or 145 nmol) required for baseline Recorlev/related agents
    QTcF interval (treatment-initiation exclusion for some oncology agents)>=450 msec or >470 msec depending on product-specific threshold
    24-hour urinary oxalate (Uox)>= 0.7 mmol (normalize to BSA if patient <18 years)
    Baseline ANC requirement (CXCR4-targeted agents)ANC <= 400 cells/mcL
    Pulmonary hemodynamics for PAH agentsPCWP <= 15 mm Hg and PVR >= 5 Wood units
    LV outflow tract (LVOT) gradient (CAMZYOS)>= 50 mmHg
    LV wall thickness (CAMZYOS)>= 15 mm (>=13 mm if familial)
    Left ventricular ejection fraction (HFrEF)< 45%
    Serum sodium threshold for tolvaptan (hyponatremia)<125 mEq/L or symptomatic <135 mEq/L resistant to fluid restriction
    Proteinuria threshold (VANRAFIA / IgA nephropathy)24-hour urine protein >= 1 g/day OR UPCR >= 0.8 g/g

    Prior Authorization, Documentation & Denial Triggers

    Prior Authorization

    General prior authorization requirement

    Prior authorization is required for drugs listed with a 'PA' on the Independent Health Medicare Advantage Part D formularies; approval must be obtained before the prescription is filled.

    Prior Authorization

    OHTUVAYRE: spirometry and prior LABA–LAMA documentation

    OHTUVAYRE prior authorization requires post-bronchodilator spirometry showing FEV1/FVC < 0.72 and FEV1% predicted between 23%–85%; documentation of current dual LABA–LAMA therapy (with or without ICS) or documentation that dual or triple therapy was ineffective, not tolerated, or contraindicated; restricted to pulmonology and age ≥18.

    • Provide post-bronchodilator FEV1/FVC and FEV1% predicted.
    • Document current dual LABA–LAMA use or prior trial/failure/intolerance of dual/triple therapy.
    • Prescriber must be pulmonology; patient age ≥18.
    Prior Authorization

    ABILIFY MYCITE: prior trial of generic aripiprazole required

    ABILIFY MYCITE PA applies to new starts only and requires documentation of at least a one-month trial of generic aripiprazole (solution, tablets, or ODT) prior to approval; prescriber restricted to psychiatry and age ≥18.

    • Submit records documenting ≥1 month trial of generic aripiprazole formulation.
    • Prescriber must be psychiatry; patient age ≥18.
    • PA applies to new starts only; coverage duration 1 year.
    Prior Authorization

    BRONCHITOL / BRUKINSA / CABLIVI: prescriber & safety documentation

    PA is required for Bronchitol, Brukinsa, and Cablivi with product-specific prescriber, safety, and prior-therapy documentation requirements: Bronchitol requires passing the Bronchitol Tolerance Test and pulmonology prescriber; Brukinsa requires diagnosis, pregnancy status, and prior systemic regimen documentation as specified; Cablivi requires confirmation of plasma exchange plus immunosuppressive therapy and submission of prior aTTP recurrences (coverage denied if >2 recurrences while on therapy).

    • Bronchitol: documentation of passed Bronchitol Tolerance Test; pulmonology prescriber; age ≥18; PA for new starts.
    • Brukinsa: submit diagnosis and pregnancy status; for follicular lymphoma submit ≥2 prior systemic regimens tried/failed; hematology/oncology prescriber; age ≥18.
    • Cablivi: confirm plasma exchange + immunosuppression; submit prior on-therapy recurrences if not first use; coverage not authorized if >2 recurrences.
    Prior Authorization

    CFTR modulators & CGRP inhibitors: mutation testing and prior therapy trials

    CFTR modulators require submission of CFTR mutation testing confirming drug-specific responsive mutation(s) and are restricted to pulmonology; CGRP inhibitors require baseline headache frequency and documentation of failure of at least two non‑CGRP alternatives (or one if contraindicated) prior to approval.

    • CFTR modulators: submit CFTR mutation test demonstrating responsive mutation per requested drug; pulmonology prescriber; PA for new starts only.
    • CGRP inhibitors: submit baseline headache days/month; document failure of ≥2 non‑CGRP prophylactic agents (or 1 if contraindicated); age ≥18; initial 3 months then reauthorization criteria.
    Prior Authorization

    DOPTELET: platelet thresholds, prescriber rules, and duration

    DOPTELET PA requires indication‑specific platelet documentation: for procedure-related thrombocytopenia submit platelet count <50 x10^9/L; for ITP submit platelet count <30 x10^9/L (or <50 x10^9/L with symptomatic bleeding) plus documentation of splenectomy and/or failure of two different ITP therapies; age ≥18 and prescriber specialty restrictions apply; PA applies to new starts and typical durations vary by indication (procedure: 5 days; ITP: initial 6 months then 1 year).

    • Procedure‑related: platelet count <50 x10^9/L and scheduled procedure; coverage 5 days.
    • ITP: platelet count <30 x10^9/L (or <50 x10^9/L with bleeding), documentation of splenectomy and/or failure of two ITP therapies; initial 6 months then 1 year for continuation.
    • Restricted prescribers: gastroenterology, hematology, hepatology, surgery; age ≥18.
    Prior Authorization

    GLP‑1 agents: PA applies; weight‑management excluded

    GLP‑1 agonist agents require prior authorization for all uses and will not be approved for off‑label weight management under Medicare Part D; diabetes diagnosis documentation per specified lab/chart criteria and attestation patient is not receiving another GLP‑1 are required.

    • Submit documentation of type 2 diabetes (medical record/chart, ICD‑10, or labs such as HbA1c ≥6.5% or fasting plasma glucose ≥126 mg/dL).
    • Attest patient is not receiving another GLP‑1 agonist; PA applies to all; weight‑management use excluded.
    Prior Authorization

    General oncology/patch/metreleptin/NUCALA PA and continuation rules

    Prior authorization applies to listed oncology, topical, metreleptin, NUCALA and other specialty products with continuation requirements: approvals are typically for new starts only and reauthorization often requires objective documentation of response (examples: metreleptin requires updated weight/metabolic labs annually; NUCALA requires objective response data for continuation).

    • PA commonly applies to new starts only; typical coverage duration 1 year.
    • Metreleptin: PA for all uses; updated weight and metabolic labs required for annual reauthorization.
    • NUCALA: PA applies to all uses; continuation requires objective documentation of positive response and maintenance intranasal corticosteroid confirmation for CRSwNP.
    Documentation Required

    NUEDEXTA & specialist PA exemptions: ECG/QT and electrolytes required

    NUEDEXTA PA requires submission of ECG/QT interval and baseline electrolytes (potassium, magnesium) as part of required documentation; some drugs in the index are exempt from PA when prescribed by specified specialists—confirm specialist exemption when applicable.

    • For NUEDEXTA submit ECG (QT interval) and baseline potassium and magnesium.
    • Check product page for specialist PA exemptions (some drugs exempt when prescribed by listed specialists).
    Prior Authorization

    TAVALISSE, Tolvaptan, Venclexta, Veozah: lab and prior‑therapy PA rules

    TAVALISSE PA requires submission of baseline platelet count (<30 x10^9/L or <50 x10^9/L with bleeding risk) and documentation of prior splenectomy and failure of two different ITP therapies; Tolvaptan (hyponatremia) PA requires evidence of serum sodium <125 mEq/L (or symptomatic <135 mEq/L resistant to fluid restriction) and is limited to 30 days; Venclexta and Veozah require diagnosis and supporting labs plus prior therapy documentation per product pages.

    • TAVALISSE: submit platelet counts and prior ITP therapy history; prescriber restricted to hematology.
    • Tolvaptan (hyponatremia): submit serum sodium meeting thresholds; treatment limited to 30 days and initiated where sodium can be closely monitored.
    • Venclexta/Veozah: submit diagnosis, supporting labs and prior therapy failures as specified.
    Note

    Indexed PA references and preferred‑agent step requirement

    Indexed PA references and step‑therapy expectations: prior authorization requirements are indexed by drug and formulation; for many biologic/targeted immunomodulators a preferred‑agent step is required (patient must try and fail the listed preferred agents where possible).

    • Consult the indexed product policy page for drug‑specific PA requirements.
    • For biologics (except Otezla and Velsipity) document trials of ≥2 preferred agents prior to approval where possible.
    Denial Risk

    Denial risks from missing prior‑therapy / step‑therapy documentation

    Prior‑therapy, step‑therapy, and denial triggers: failure to document required prior therapies or comparator trials (e.g., statin/ezetimibe for PCSK9 inhibitors, trials of non‑CGRP alternatives for CGRP inhibitors) or missing documentation are common reasons for denial.

    • PCSK9 agents require statin+ezetimibe use or documentation of ≥2 statin failures including a hydrophilic statin.
    • CGRP inhibitors require failure of ≥2 non‑CGRP prophylactic agents (or one if contraindicated) with baseline headache days submitted.
    • Absence of required prior therapies or documentation may result in denial.
    Note

    Consult individual drug policy pages for full PA requirements

    Index limitations and provider instruction: this index is an index only and does not contain complete documentation instructions — providers must consult each drug's specific policy page for exact required supporting tests, thresholds, and prior‑therapy lists.

    • Refer to the individual drug policy page referenced in the index for full documentation requirements.
    • Do not rely solely on the index for detailed lab thresholds, mutation testing, or step‑therapy lists.

    Initial Authorization Criteria (Selected Products)

    Reauthorization & Continuation Requirements

    Required Prior Therapy & Step Rules

    Step therapy ruleApplies to / examplesRequired prior trial(s) or condition
    Preferred-agent class-level stepBiologic and targeted immunomodulators (class-level) — general policyPatient must have tried and failed at least two preferred agents (e.g., adalimumab biosimilar, Cosentyx, Enbrel, Humira, Rinvoq, Skyrizi, ustekinumab biosimilar, Xeljanz/XR) prior to approval (except Otezla and Velsipity). Baseline latent TB screening required; yearly TB screening/chest x‑ray for reauthorization when exposure risk exists.
    Lipid‑therapy stepNEXLETOL / NEXLIZETPatient must currently be using a statin plus ezetimibe OR have tried and failed/been intolerant to at least two statins or one statin plus ezetimibe; at least one previously tried statin must be hydrophilic. PA applies to new starts only.
    CGRP inhibitor non‑CGRP alternative stepCGRP monoclonal antibodies for migraine prevention (Aimovig, Ajovy, Emgality, others)Failure of at least two non‑CGRP FDA‑approved or compendial alternatives (propranolol, timolol, topiramate, valproic acid, amitriptyline, etc.) required (or one if contraindicated). Emgality prevention additionally requires prior failure of Aimovig and Ajovy. Initial approval 3 months then 1 year.
    Antipsychotic stepCertain second‑generation/atypical antipsychotics (schizophrenia, bipolar indications)For schizophrenia/acute manic/mixed bipolar I: trial and inadequate response or intolerance to aripiprazole and at least one other generic second‑generation atypical antipsychotic required prior to approval.
    Biosimilar / Zarxio step (granulocyte colony‑stimulating factors)Neupogen/filgrastim use (most indications) — Zarxio preferredTrial and failure or intolerance to Zarxio required before approval of Neupogen for indications other than hematopoietic syndrome of acute radiation syndrome.
    C5 inhibitor prerequisiteC5 inhibitor‑treated conditions (e.g., PNH entries)Documentation of prior use/intolerance/failure of a C5 inhibitor (eculizumab or ravulizumab) required where specified before other products will be approved.
    ROS1 sequencing/prior TKI requirementROS1‑positive tumor targeted agentsFor initial authorization, patient must have tried and failed crizotinib or entrectinib or have contraindications to both prior to approval; tumor ROS1 positivity test required.
    Line‑of‑therapy requirements (hematology)Select hematology/oncology agents (mantle cell lymphoma, CLL/SLL, others)Documentation that patient tried and failed at least two prior systemic therapies; for mantle cell lymphoma one prior line must include a BTK inhibitor; for CLL/SLL prior lines must include BTK and BCL‑2 inhibitors where specified.
    Therapy‑experience affects durationHCV direct‑acting antivirals (ledipasvir‑sofosbuvir, others)Treatment‑experienced patients with genotype 1 and compensated cirrhosis may require longer duration (e.g., 24 weeks) versus 12 weeks for others; prior therapy status must be documented.
    Prior stimulant / wakefulness agent trialsSolriamfetol and other wakefulness agents (narcolepsy/excessive daytime sleepiness)Authorization only if patient previously tried and had inadequate response, intolerance, or contraindication to armodafinil or modafinil (solriamfetol also requires prior trial of armodafinil/modafinil per policy). Baseline BP required.
    Statin + ezetimibe / PCSK9 prerequisite (lipid agents)PCSK9 inhibitors (Repatha, Praluent) and related lipid therapiesPatient must be currently using a statin plus ezetimibe OR have tried and failed at least two statins or one statin plus ezetimibe; at least one prior hydrophilic statin trial required.
    Maximally‑tolerated RAS inhibitor + SGLT2 stepVANRAFIA and primary IgA nephropathy agents; select nephrology productsInitial authorization requires patient currently using (or contraindicated to) maximally‑tolerated ACE inhibitor or ARB AND tried and failed or been intolerant to at least one SGLT‑2 inhibitor (e.g., dapagliflozin, empagliflozin); biopsy confirmation and proteinuria thresholds required.
    Background PAH therapy requirementPulmonary arterial hypertension (PAH) therapiesMember must be using, unless contraindicated, at least one drug in at least two of these classes: nitric oxide pathway mediator, endothelin receptor antagonist, and prostacyclin pathway agonist prior to approval; baseline hemodynamics (PCWP ≤15 mm Hg and PVR ≥5 Wood units) and functional tests required.
    Antibiotic trial requirement for SIBO/IBS‑DRifaximin 550 mg (SIBO, IBS‑D, HE)For SIBO require positive carbohydrate breath test and trial/failure of at least two prior antibiotics; for IBS‑D require failure of at least one antidiarrheal/antispasmodic/tricyclic; course limits apply (14‑day courses, maximum two per 365 days for IBS‑D).
    Tyrosine kinase inhibitor sequencingSCEMBLIX and other TKIs with mutation‑specific sequencingFor T315I mutation patients, must have tried and failed or been intolerant to ponatinib; for non‑T315I use must have tried and failed two or more other TKIs as specified.
    Prior systemic therapy documentation required (oncology examples)Various oncology targeted agents (e.g., tovorafenib pediatric, MET/RET/ALK/ROS1 agents)Submission of prior systemic therapies tried/failed and relevant molecular testing (BRAF, MET, RET, ALK, ROS1, NTRK etc.) required for initial authorization; PA typically applies to new starts only.
    Hydrophilic statin requirement noted (lipid step) — cross‑referenceNEXLETOL/NEXLIZET, PCSK9 pathwaysAt least one previously tried statin must be a hydrophilic statin when documenting prior statin failures per lipid‑therapy step rules.
    Stimulant/solriamfetol sequencing for refractory casesPitolisant / other narcolepsy agents in some pathwaysSome excessive daytime sleepiness approvals require documentation of trials of armodafinil/modafinil and solriamfetol (sequencing varies by drug); updated labs (electrolytes) may be required for certain agents.

    Quantity Limits and Place-of-Service Guidance

    Digoxin PA exemption (contextual)
    Digoxin low-dose PA exemptionDoses less than or equal to 0.125 mg/day are exempt from prior authorization
    Age/prescriber PA notesPA for digoxin applies to patients 65+; PA not required when prescribed by cardiology
    Trial requirement for non-exempt dosesPatient must have tried and failed to respond adequately to 0.125 mg digoxin before PA is required for higher doses
    Billing Rule

    Site‑of‑care: Part B vs Part D and infusion vs pharmacy

    Site‑of‑care determinations affect coverage (Part B vs Part D): confirm whether the drug will be administered in‑office/infusion center or self‑administered and document site‑of‑care details, since some drugs (e.g., ARIKAYCE, immune globulins) may be Part B when administered in provider settings but Part D when dispensed through pharmacy.

    • ARIKAYCE: Part B coverage except for enrollees in long‑term care facilities; when dispensed under Part D follow Part D PA rules.
    • For immune globulins and similar agents, provide administration setting to determine Part B vs Part D coverage.
    • If therapy is to be self‑administered after training or filled at pharmacy and delivered to office by patient, Part D coverage may apply.

    Key Definitions & Clinical Thresholds

    Definitions / required diagnostic tests and thresholds
    Prior Authorization (PA)Payer approval required before the prescription is filled for coverage under the Medicare Advantage Part D formularies
    Creatinine clearanceLab value (or serum creatinine plus weight/height) submitted when required to assess renal function for dosing/eligibility
    CFTR mutation confirmationSubmission of CFTR mutation test confirming presence of responsive CFTR gene mutation(s) as specified per CFTR modulator requested
    LVOT gradient (CAMZYOS)LV outflow tract obstruction gradient >= 50 mmHg (rest/Valsalva/after exercise) required
    EoE confirmationUpper endoscopy with biopsy showing >=15 eosinophils per high-power field or 60 eosinophils/mm2
    SMA genetic confirmationSMN1/SMN2 testing confirming homozygous deletion of SMN1 exon 7 or compound heterozygosity plus SMN2 copy number documentation
    Eosinophil thresholds (mepolizumab/NUCALA)>=150 cells/mcL within 6 weeks of initiation OR >=300 cells/mcL within 12 months; for EGPA >=10% or AEC >=1000 cells/mm3 from prior 6 weeks
    Hepatic impairment classesModerate or severe hepatic impairment referenced as Child-Pugh class B or C (exclusion for multiple products)
    24‑hour UFC requirementBaseline 24-hour urine free cortisol >1.5 x ULN required for Cushing's therapies (e.g., Recorlev)
    Phenylalanine threshold (PALYNZIQ)>600 micromol/L while using sapropterin required for initial approval
    QTcF exclusionQTcF interval >450 msec is an exclusion for specified products
    Uox threshold (primary hyperoxaluria)>=0.7 mmol/24 hr (normalize to BSA if <18) required
    ATTR diagnostic confirmationCardiac biopsy with amyloid deposits, immunohistochemistry, technetium‑99 scintigraphy/SPECT, or TTR mutation plus cardiac involvement
    UPCR (proteinuria)UPCR = urine protein-to-creatinine ratio; PA proteinuria threshold defined as UPCR >= 0.8 g/g (or 24‑hr urine protein >=1 g/day)

    Policy Background & Scope

    This policy index defines clinical prerequisites and explicit exclusions that apply across many high‑cost and specialty drugs on Independent Health’s Medicare Advantage Part D formularies. Providers must obtain prior authorization (PA) when a product is designated with PA on the formulary; lack of an approved PA may result in the drug not being covered for the Medicare Advantage Part D enrollee. Many entries require submission of objective baseline data (for example, creatinine clearance or eGFR, ECG/QTcF, LFTs, 24‑hour urine tests, tumor or genetic testing, or disease‑specific measures such as FEV1 or platelet counts) and confirmation of pregnancy status for females of childbearing potential. (See product‑specific sections for exactly which tests and thresholds are required.)

    Where applicable, this index emphasizes common exclusion criteria that will trigger denial: moderate–severe hepatic impairment (Child‑Pugh B or C), severe renal impairment or eGFR <30 mL/min/1.73 m2, coadministration with specified strong CYP3A4 inducers or inhibitors, recent non‑selective MAOI use, congenital long QT syndrome or prolonged QTcF above stated limits, known mechanical GI obstruction for certain agents, and pregnancy when listed as an exclusion. Other frequent denial triggers include absence of required molecular or genetic testing (e.g., CFTR, RET, FGFR, ALK/ROS1), failure to document mandated prior therapy trials or step‑therapy attempts, and requests for uses explicitly excluded under Medicare Part D (for example, GLP‑1 agonists for weight management or tadalafil for erectile dysfunction under the listed product entry).

    The index also summarizes administrative expectations: PA commonly applies to new starts only, typical initial coverage durations are short courses (14–90 days) or up to 6 months for some agents with subsequent annual reauthorization, and many chronic specialty drugs are authorized for 1 year when required documentation is provided. Prescriber specialty restrictions (oncology, pulmonology, cardiology, nephrology, endocrinology, etc.) and site‑of‑care considerations (Part B vs Part D determinations when a product is administered in‑office or self‑administered) are noted and must be satisfied to determine coverage pathway and to complete the PA request.

    Revision History

    2025-10-01policy_effective_dateLatest

    Prior Authorization Criteria list effective for Independent Health Medicare Advantage Part D formularies; document current as of 10/1/2025.

    2025-10-01content_update

    Multiple product-specific prior authorization requirements, exclusions, and required documentation items summarized and indexed for 2025 formulary; examples include OHTUVAYRE, ARIKAYCE, CFTR modulators, and many oncology and specialty agents.

    Policy Summary
    PayerIndependent Health
    PolicyMedicare Part D Prior Authorization Criteria (selected drugs)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization before dispensing drugs listed with 'PA' on the Medicare Advantage Part D formularies.
    SourceLink
    On This Page
    Product-level Coverage CriteriaIndexed Product Coding & Key Numeric ThresholdsPrior Authorization, Documentation & Denial TriggersInitial Authorization Criteria (Selected Products)Reauthorization & Continuation RequirementsRequired Prior Therapy & Step RulesQuantity Limits and Place-of-Service GuidanceKey Definitions & Clinical ThresholdsPolicy Background & ScopeRevision History

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.